Strategic Collaboration Rectify Pharma recently entered a strategic research and licensing agreement with Boehringer Ingelheim to accelerate development for chronic kidney disease and other conditions, signaling a potential channel for co-development or license partnerships and a ready-made credibility boost for BD discussions.

Clinical Progress Preclinical proof of concept data for their hepatobiliary program was presented at EASL 2025, highlighting near-term opportunities to engage in co-development, advisory roles, or funding partnerships around liver and hepatobiliary indications.

Focused Platform PFMs target restoration of membrane protein function across wild-type and mutated forms, with applications in liver, cardio-renal-metabolic, and neurodegenerative diseases, offering multiple adjacent market entries for strategic alliances or milestone-driven deals.

Leadership & Talent Key executive hires include a CMO with transporter-focused expertise and experienced board/advisory additions, suggesting openings for advisory collaborations, KOL-engagement programs, or executive placement in partner-led programs.

Funding & Scale With a seed-to-series A backing of 100M and a current revenue range of 1M-10M, Rectify presents an attractive profile for early-to-mid stage partnerships, licensing opportunities, and potential investor-backed co-development ventures seeking moderate risk and milestone-driven returns.